On Tuesday, shares of biopharmaceutical company Arena Pharmaceuticals (NASDAQ:ARNA) are skyrocketing, up about 41% to $26.10 per share in afternoon trading after it reported positive mid-stage trial results for one of its drugs. The …
Here is the rundown on market activity for Arena Pharmaceuticals, Inc. (NASDAQ:ARNA). Amit Munshi, President and CEO disclosed the purchase of 25,000 shares of ARNA stock. The shares were bought on May 12th for an average …
The stock has "Buy" rating by Stifel Nicolaus on Monday, October 19. Media coverage about Arena Pharmaceuticals (NASDAQ:ARNA) has trended somewhat positive recently, according to Accern Sentiment Analysis. The firm had …
They now have a Dollars 12 price target on the stock. Market Capitalization can be thought of as the overall price to buy the company. Arena Pharmaceuticals, Inc. has a 50 day moving average of 13.76 and a 200 day moving average of …
Investors in Arena Pharmaceuticals Inc (NASD: ARNA) saw new options become available today, for the November 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARNA options chain for the …
Many brokerage firms have weighed in on ARNA. Among 19 analysts covering Zoetis Inc (NYSE:ZTS), 14 have Buy rating, 1 Sell and 4 Hold. Cantor Fitzgerald reiterated an "overweight" recommendation and given a $37.00 target price on …
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) is having an incredibly strong start to the trading session this morning, and for good reason. The company released positive data from a key Phase 2 clinical trial. As you would imagine, this led …
Trading volume may be a very important factor for any investor. But action on Court One, where two of the women's last-eight match were on the programme, was delayed. Milos Raonic , the sixth seed, made short work of No. 25 Antonio …